Price history
¥1,529Latest-7.9%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
A summary lands here once the filings have been read.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 20
PER
29How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
2.86How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
9.9%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥164bnShare price × number of shares. The value of the entire company.Equity ratio
91.6%The proportion of assets funded by money that does not have to be repaid.Operating margin
30.7%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
9.6%The average annual growth in sales over the past three years.What to watch next
Disclosure of progress on the start of JIZAI mass production in September 2026 and the planned launch of JIZAI-3, which uses a new material
Around September 2026Impact HighLikelihood Medium
Progress in ramping up sales and expanding distribution channels for 27G and 25G vitreous forceps following their launch in Japan in April 2026, including in the United States, Europe, India and China
April 2026 through the second half of 2026Impact MediumLikelihood Medium
Updates on the voluntary recall and change application for MANI diamond burs in China, including the status of certification and sales resumption, any reduction in affected products, and whether sales can restart
From 2025 onward, depending on the timing of the next disclosureImpact HighLikelihood Medium
Improvement in productivity, quality and cost metrics through the smart factory at the Hanaoka plant, with the effects to be assessed from 2026 onward
2026–2028Impact MediumLikelihood Medium
Signs of improved profitability from the restructuring of the European MMG dental business, including a review of transaction terms with 80 OEM customers and initiatives to develop business jointly with them
From 2026 onward, as the initiative is still in its ramp-up phaseImpact MediumLikelihood Low
What to watch next
Who owns itTop holders total 45.3%
Listed holders 45.3%Everyone else 54.7%
The Master Trust Bank of Japan, Ltd. (Trust Account)11.44%
マニックス株式会社10.76%
松谷技研株式会社5.16%
株式会社日本カストディ銀行 (Trust Account)4.11%
公益財団法人マニー松谷医療奨学財団3.25%
NORTHERN TRUST CO. (AVFC) RE UKUC UCITS CLIENTS NON LENDING 10PCT TREATY ACCOUNT2.46%
松谷 貫司2.14%
株式会社正光2.08%
2 other listed holders3.89%
| Holder | Ownership (%) |
|---|---|
| The Master Trust Bank of Japan, Ltd. (Trust Account) | 11.44 |
| マニックス株式会社 | 10.76 |
| 松谷技研株式会社 | 5.16 |
| 株式会社日本カストディ銀行 (Trust Account) | 4.11 |
| 公益財団法人マニー松谷医療奨学財団 | 3.25 |
| NORTHERN TRUST CO. (AVFC) RE UKUC UCITS CLIENTS NON LENDING 10PCT TREATY ACCOUNT | 2.46 |
| 松谷 貫司 | 2.14 |
| 株式会社正光 | 2.08 |
| 2 other listed holders | 3.89 |
This company's documents
Filings
Timely disclosures
- 2026-10-15Notice Regarding Differences Between Full-Year Non-Consolidated Results for the Fiscal Year Ending August 2026 and the Previous Fiscal Year’s Results
- 2026-10-15Financial Results for the Fiscal Year Ending August 2026 [Japanese GAAP] (Consolidated)
- 2026-09-10Notice Regarding the Capital and Business Alliance with Swiss Company Odne AG
- 2026-07-30Mani: Notice Regarding the Launch of Its 70th Anniversary Website
- 2026-07-15Flash Report on Financial Results for the Third Quarter of the Fiscal Year Ending August 2026 [Japanese GAAP] (Consolidated)
- 2026-07-15Notice Regarding Upward Revision to Full-Year Earnings Forecast
- 2026-06-23Notice Regarding Changes to the Executive Structure
- 2026-05-21Launch of the dental carbide bur "1559L" for use in tooth sectioning
40 more
- 2026-04-24First-Time Recognition as “Prime Status” in ISS ESG’s ESG Corporate Rating
- 2026-04-14Notice Regarding Differences Between the Consolidated Earnings Forecast for the Cumulative Second Quarter of the Fiscal Year Ending August 2026 and Actual Results
- 2026-04-14Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending August 2026 [Japanese GAAP] (Consolidated)
- 2026-03-27Notice of Publication of Integrated Report 2025 (Japanese Version)
- 2026-03-16Notice of Interview Articles Published in The Worldfolio and the International Edition of Newsweek
- 2026-01-26マニー、緑内障手術用「マニートラベクロトミーフック」を新発売
- 2026-01-16CDP2025気候変動分野で「B」スコア獲得
- 2026-01-14中国生産子会社の設立に関するお知らせ
- 2026-01-142026年8月期 第1四半期決算短信[日本基準](連結)
- 2025-12-22ドイツiRIS EYE GmbHの持分取得(持分法適用関連会社化)に関するお知らせ
- 2025-12-05スマートファクトリー紹介動画公開のお知らせ
- 2025-11-07当社「マニーダイヤバー」自主回収に対する役員の処分に関するお知らせ
- 2025-10-30中華人民共和国における「マニーダイヤバー」販売再開のお知らせ
- 2025-10-28第66期定時株主総会 その他の電子提供措置事項(交付書面省略事項)
- 2025-10-28第66期 定時株主総会 招集ご通知
- 2025-10-24米ニュース雑誌「TIME」掲載のお知らせ
- 2025-10-22サプライヤー行動規範を制定
- 2025-10-08Notice Regarding the Selection of Director Candidates
- 2025-10-082025年8月期 決算短信[日本基準](連結)
- 2025-10-06マニー、眼科手術用「コントロールヘッド」ナイフを新発売 狙い通りの切開を実現する、コントロール性と切れ味を両立した新設計
- 2025-10-03栃木県子ども総合科学館リニューアルに寄贈 体験型展示で医療技術の魅力を発信
- 2025-08-05マレーシア販売子会社のアジア地域統括拠点化のお知らせ
- 2025-07-16CDP気候変動分野で「B-(マイナス)」評価獲得 に関するお知らせ
- 2025-07-09Notice Regarding Revisions to Full-Year Earnings Forecast
- 2025-07-092025年8月期 第3四半期決算短信[日本基準](連結)
- 2025-06-23Notice Regarding Changes to the Executive Structure
- 2025-06-06スマートファクトリー(花岡工場)におけるPPA(電力購入契約)サービス利用開始のお知らせ
- 2025-04-18米国Microsurgical Technology社との戦略的パートナーシップ契約締結について
- 2025-04-09Notice Regarding Changes in Officers
- 2025-04-09Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending August 2025 [Japanese GAAP] (Consolidated)
- 2025-04-09中華人民共和国における「マニーダイヤバー」の自主回収に関するお知らせ
- 2025-01-142025年8月期第1四半期決算短信〔日本基準〕(連結)(公認会計士等による期中レビューの完了)
- 2025-01-082025年8月期 第1四半期決算短信[日本基準](連結)
- 2024-12-20Notice of Completion of Payment for the Disposal of Treasury Shares as Restricted Stock-Based Compensation
- 2024-11-25当社執行役に対する譲渡制限付株式報酬としての自己株式の処分に関するお知らせ
- 2024-11-25Articles of Incorporation 2024/11/25
- 2024-11-01第65期定時株主総会その他の電子提供措置事項(交付書面非記載事項)
- 2024-11-01Notice of Convocation of the 65th Annual General Meeting of Shareholders
- 2024-10-16(訂正)「2024年8月期 決算短信〔日本基準〕(連結)」の一部訂正について
- 2024-10-09(訂正)2024年9月11日に公表したPR情報の一部訂正について
Threads
- 2026-10-15Local Marketing and Sales Network Development Focused on China and Vietnam
- 2026-10-15Delays in Reorganizing the Chinese Sales Network and Weak Sales in Emerging Markets
- 2026-10-15Construction of a New Vietnam Plant to Accommodate Future Order Growth
- 2026-10-15Developing and Launching New Products for Advanced Markets
- 2026-10-15Capital-Market Funding as an Option for New-Business Investment and Strengthening Equity
- 2026-10-15Consolidated Dividend Payout Ratio of Approximately 30%, with a Medium- to Long-Term Target of 40%
- 2026-10-15Foreign-Exchange Risk from Overseas Sales and Foreign-Currency Transactions
- 2026-10-15Impact on segment profit from higher selling, general and administrative expenses
100 more
- 2026-10-15Strengthening competitiveness and marketing through the establishment of the Dental Business Division
- 2026-10-15Production Delays in Dental Restorative Materials Following the Launch of MMG’s New Headquarters and Plant
- 2026-10-15Upward revision to the full-year earnings forecast for the fiscal year ending August 2026
- 2026-10-15Odne社との資本業務提携による根管治療製品ポートフォリオ拡大
- 2026-10-152027年8月期の連結業績予想
- 2026-09-10Globalization of operations, production and development and transformation of the business model under the Medium-Term Management Plan
- 2026-07-30Achieving and Maintaining the “World’s Highest Quality”
- 2026-07-15Expanding Sales in Advanced Markets
- 2026-07-15Trends in Revenue Growth and Profit Levels
- 2026-07-15Risk of Medical Device Defects, Recalls and Litigation
- 2026-07-15Weak Orders in Emerging Markets Due to Inventory Adjustments by Large Overseas Customers
- 2026-07-15Recovery of China Diamond-Bur Sales to Pre-Recall Levels
- 2026-06-23Changes in Executive Responsibilities
- 2026-05-21R&D of Core Medical and Dental Products and Foundational Technologies
- 2026-04-24Compliance and Quality, Environmental, and Occupational Health and Safety Management Systems
- 2026-04-24Balancing Sustainable Growth with a Sustainable Society Through MANI Sustainability
- 2026-04-14Slower Growth in Emerging Markets, Intensifying Competition, Group Purchasing and Yen Appreciation
- 2026-04-14Low margins on SDG products and the burden of goodwill amortization
- 2026-04-14Continued Investment in Research and Development
- 2026-04-14Payment of dividends funded by retained earnings
- 2026-04-14Agile Capital Policy Through Share Buybacks
- 2026-04-14Change of Audit Firm
- 2026-04-14Increase in Operating Cash Flow and Cash Balance
- 2026-04-14Declines in Selling Prices Due to Changes in Healthcare Policy
- 2026-04-14Cancellation of Medical Device Approvals and Changes in Laws and Regulations
- 2026-04-14High Equity Ratio
- 2026-04-14Acquisition of Land for the Expansion of Headquarters and Domestic Plant Facilities
- 2026-04-14Stable Product Supply System through BCP Measures
- 2026-04-14Disaggregated Revenue by Region
- 2026-04-14Strengthening the European Ophthalmic Sales Structure Through an Investment in iRIS
- 2025-11-18Outlook for Overall Expansion of the Medical Device Market
- 2025-11-18Country Risk at Overseas Bases and Risk of Product Supply Disruptions
- 2025-11-18Separating oversight and execution through a company with a three-committee board structure
- 2025-11-18Management Metrics Focused on Operating Profit Growth, Margins and Capital Efficiency
- 2025-11-18Concentration of Trade Receivables Among Certain Large Customers
- 2025-11-18Performance-Linked Compensation and Performance Unit Plan
- 2025-11-18Percentage of Women Among Executives
- 2025-11-18Reducing CO2 Emissions Including Those of Group Companies
- 2025-11-18Energizing the Organization Through Diversity Initiatives
- 2025-11-18Profit pressure from higher manufacturing costs at overseas subsidiaries
- 2025-11-18Human Capital Strategy for Globalization, Diversity and Employee Engagement
- 2025-11-18Achieving a Female Manager Ratio of at Least 15%
- 2025-11-18Human Capital Metrics Including Investment in Talent Development and Experienced-Hire Ratios
- 2025-11-18Review of Medium- and Long-Term Corporate Strategy by the Strategy Committee
- 2025-11-18Establishing a Green Supply-Chain Assessment System
- 2025-11-18Declining Organizational Capabilities Due to Personnel Outflows and Vacancies in Key Positions
- 2025-11-18Sales Partnership for Ophthalmic Products with US-based MicroSurgical Technology
- 2025-04-11Physician- and Dentist-Focused Marketing and the Commercialization of Knowledge and Information
- 2025-04-11Management Platform Reform and Change in the Representative Executive President
- 2024-11-26Expansion of Overseas Production and High Export Ratio
- 2024-11-26Risk of Product Supply Disruptions Due to Natural Disasters
- 2024-11-26Sale of Shares in Line with the Corporate Governance Code’s Policy of Reducing Cross-Shareholdings
- 2024-11-26Issuance of Common Shares as Restricted Stock Compensation
- 2024-11-26Climate Change, Extreme Weather and Transition Risks from the Shift to a Low-Carbon Society
- 2024-11-26Risk of Business Disruption and Information Leakage from Cyberattacks
- 2024-11-26Change in the Method of Calculating Segment Profit Following the Establishment of the Dental Business Division
- 2024-11-26Formulation of the MANI Group Human Rights Policy and Human Rights Due Diligence
- 2024-07-12Developing SDG into a European Sales and R&D Base
- 2024-07-12Long-term, global management rooted in high quality and trust with physicians
- 2024-07-12Decline in Sales of High-Margin Surgical Products
- 2024-07-12Higher Raw-Material and Transportation Costs and Supply-Chain Disruptions
- 2023-11-22Healthcare Cost Containment and Tighter Approval Standards in Developed Markets
- 2023-11-22Production Transfer to the Vietnam Plant, Improvements in Efficiency, Quality and Costs, and Direct Shipment
- 2023-11-22Risk of Excessive Concentration of Production in Vietnam
- 2023-11-22Strengthening Governance and Internal Controls at Overseas Operations and Sharing Corporate Culture
- 2023-11-22Extended Commercialization and Approval Timelines for New Products and Technologies
- 2023-11-22Contributing to the world through products that benefit patients and physicians and maximizing future profits
- 2023-11-22Independence Standards and Oversight Functions of Outside Directors
- 2023-11-22Impact of Delayed Cost-Improvement Initiatives on Dental Profit
- 2023-11-22Business Impact of the Spread of COVID-19
- 2023-11-22Concentration of Sales among Major Customers
- 2023-11-22Deterioration in the Cost-of-Sales Ratio and Pressure on Needle-Related Product Profit from Disposal of Unsaleable Inventory
- 2023-11-22Investment Returns and Excess-Capacity Risks Related to the Smart Factory and New Vietnam Plant
- 2023-07-14Securing Flexible and Stable Funding Through Commitment-Line Agreements
- 2023-07-14Adoption of the Accounting Standard for Fair Value Measurement
- 2022-07-15Dental profit pressured by a higher sales mix of low-margin products
- 2022-07-15Application of the Revenue Recognition Accounting Standard in the Fiscal Year Ending August 2022
- 2022-01-14Strengthening Controls, Preventing Recurrence and Restoring Trust Following a Voluntary Product Recall
- 2021-11-25Alternative production, recovery and recurrence prevention following the fire at the company's Vietnam Plant No. 1
- 2021-11-25Alignment of Overseas Subsidiaries’ Reporting Dates and Change in Consolidation Method Through Interim Closing
- 2021-07-14Deteriorating Consumer Sentiment from the Consumption Tax Increase and Uncertainty About the Domestic Economic Outlook
- 2021-04-14Risk of Declines in the Value of Investment Securities and Investee Companies
- 2021-04-14Investment in Shanghai Lichi Medical Technology Co., Ltd. and Application of the Equity Method
- 2021-01-14Change in the classification of Ailess needle-related products following a review of performance management categories
- 2021-01-14Change in the Display Unit for Amounts in Quarterly Consolidated Financial Statements
- 2020-11-26Application of IFRS 16, “Leases,” to Certain Overseas Subsidiaries
- 2020-11-26Accounting Estimates Based on an Assumption That COVID-19 Would Largely Subside by the End of the Fiscal Year Ending August 2021
- 2020-07-15Discontinuation of Low-Profit, Difficult-to-Improve Dental Microscopes and Other Products
- 2020-01-14Preparing Domestic Factories for Mass Production of New Products and Coordinating with Overseas Production Bases
- 2019-11-25Lowering the Investment Unit and Improving Liquidity through a Share Split
- 2019-07-12Temporary increase in costs due to preparations for transferring production processes to the new factory in Vietnam
- 2018-07-13Expansion of Production Capacity and Development of a Quality Management System at the Myanmar Plant
- 2018-07-13Weak sales to Russia
- 2018-04-13Stabilizing Operations at the Laos Base
- 2017-11-24Aligning the Interests of Customers, Employees and Shareholders
- 2017-11-24Balancing short-term results-driven development with long-term new product development
- 2017-11-24Weak implant sales at SDG
- 2016-11-28Decline in Directors’ Shareholding Ratios and Potential Changes in Shareholder Composition
- 2016-11-28Risk of Damage to Enterprise Value and Common Shareholder Interests from Inappropriate Purchases
- 2016-11-28Information Submission and Special Committee Procedures for Large-Scale Purchases of 20% or More